Skip to search formSkip to main contentSkip to account menu

Dipeptidyl Peptidase 4 Inhibitor [EPC]

Known as: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, Dipeptidyl-Peptidase IV Inhibitor, DPP-4 Inhibitor 
National Institutes of Health

Related topics

Related topics

3 relations
Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl Peptidase-4 InhibitorDipeptidyl-Peptidase IV Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study
Aims/hypothesis IL-6 is a cytokine with various effects on metabolism. In mice, IL-6 improved beta cell function and glucose… 
2016
2016
In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
Nanoparticles are promising carrier systems for the oral delivery of proteins, a challenge in the pharmaceutical field. 
Highly Cited
2013
Highly Cited
2013
Trends in antidiabetic prescription patterns in Japan from 2005 to 2011.
There have been few reports concerning the trends in antidiabetic drug use in Japan. In 2009, a dipeptidyl peptidase-4 inhibitor… 
Highly Cited
2013
Highly Cited
2013
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Highly Cited
2012
Highly Cited
2012
Metabolic Surgery for Non-Obese Type 2 Diabetes: Incretins, Adipocytokines, and Insulin Secretion/Resistance Changes in a 1-Year Interventional Clinical Controlled Study
Objective: To compare duodenal-jejunal bypass (DJB) with standard medical care in nonobese patients with type 2 diabetes and… 
Review
2012
Review
2012
A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
IntroductionWhile incretin-based therapies have been compared in clinical trials, data comparing their relative efficacy in… 
Highly Cited
2011
Highly Cited
2011
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Highly Cited
2006
Highly Cited
2006
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
ABSTRACT Objective: As part of the clinical development of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of… 
Highly Cited
2006
Highly Cited
2006
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors.
This paper describes the design and synthesis of dipeptidyl N,N-dimethyl glutaminyl fluoromethyl ketones (fmk) as severe acute… 
1967
1967
The synthesis of glycyl-L-phenylalanyl-sRNA.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)